放射性塞栓療法の世界市場：成分別、治療カテゴリー別、腫瘍タイプ別、適用手順別、エンドユーザー別-2025-2030年予測

放射性塞栓療法市場は、2024年に10億9,000万米ドルと評価され、2025年には11億5,000万米ドル、CAGR 5.90%で成長し、2030年には15億4,000万米ドルに達すると予測されています。

放射性塞栓療法は、肝がんの治療において画期的なソリューションとして登場し、従来の治療法では挫折しがちな状況に希望をもたらしています。本エグゼクティブサマリーでは、高度な医療技術と重要な患者ケアの融合点に立つ市場の複雑な詳細を探る。技術革新が急速に進展し、がん標的治療への注目が高まる中、本分析では、この変革的な分野における現在の動向、新たな課題、ビジネスチャンスについて解説します。

近年、医療関係者や研究者の間で、肝腫瘍を高精度で狙い撃ちし、健康な組織への付随的なダメージを軽減する低侵襲治療法として、放射性塞栓療法への注目が高まっています。この制御された体内照射は、がん治療における個別化の重要性を強調するだけでなく、原発性・転移性肝がんとの闘いにおける治療基準を再定義するものでもあります。ここで提供する戦略的洞察は、意思決定者、ヘルスケアイノベーター、業界リーダーに、現在の市場ダイナミクス、主要成長要因、さらなるイノベーションが必要な分野の包括的な概要を提供することを目的としています。

臨床応用、技術的進歩、業界の中心的企業の影響力を徹底的に調査することで、当面の戦術的転換と長期的な戦略立案の両方をサポートするロードマップを提示することを目的としています。本レポートは、臨床エビデンスと市場データ分析を融合させたバランスの取れた視点により、複雑な放射線塞栓療法分野をナビゲートしようとする利害関係者にとって不可欠なガイドとなります。

現代の放射線塞栓療法を牽引する変革的シフト

近年、放射線塞栓療法の状況は大きく変化しています。技術革新と腫瘍生物学および放射線物理学に対する理解の深まりが、治療戦略のパラダイムシフトを引き起こしました。この進化は、高度な画像技術、精密に設計された送達システム、および標的線量をこれまで以上に効果的に送達するように設計された新規の放射性微小球の統合によって強調されています。

カテーテル設計の進歩は、注入プロセスの精度と安全性を向上させ、放射性塞栓療法の治療指数をさらに高めています。このような技術的改良を補完するものとして、治療計画やリアルタイムのモニタリングを強化する画像診断モダリティの採用があり、これによって臨床的信頼性が高まっています。さらに、さまざまな地域で規制の枠組みや償還政策が進化していることも、こうした革新的な治療法へのアクセスや受け入れの拡大に道を開いています。

医師、技術者、医療機器メーカー間の協力関係の高まりも、技術革新のペースを加速させています。利害関係者は現在、臨床の専門知識と技術力の相乗効果を利用することができ、それによって放射性塞栓療法の全体的な効果を高めています。個別化された治療レジメンに重点を置くことで、市場は画一的なアプローチから、よりカスタマイズされた精密ベースの手法へと移行しつつあり、現代の腫瘍学的治療におけるその役割はさらに確固たるものとなっています。

この変革の道のりには課題がないわけではないです。伝統的なヘルスケアの枠組みに新しいテクノロジーを統合するには、広範なトレーニングと開業医のプロトコルの再調整が必要です。それにもかかわらず、患者の転帰の改善や全身毒性の軽減といった潜在的なメリットが、この分野における治療戦略の絶え間ない進化を促しています。

市場力学を明らかにするセグメンテーションの洞察

放射性塞栓療法市場をより深く理解するには、いくつかの主要なセグメンテーションを正確に分析する必要があります。市場は、カテーテル、核医学装置、放射性微小球、X線装置などの高度な装置を含むコンポーネント分析に基づいて解剖されます。このセグメンテーションにより、各コンポーネントがシームレスな治療プロセスを促進する上で極めて重要な役割を果たし、技術が安全基準や業務効率に適合していることを理解することができます。

さらに、市場は治療カテゴリーというレンズを通して分析され、治療的アプローチと緩和的アプローチを区別しています。このような区別は、放射性塞栓療法の二面性を強調するものであり、ある患者は疾患の根絶を意図して根治的な治療を求め、またある患者は難治性疾患に直面してQOLの向上を目的とした緩和的治療を選択します。この二面性が、臨床効果と患者中心のアウトカムのバランスを取ろうとするメーカーの技術革新に拍車をかけています。

さらに、腫瘍の種類を細分化することで、転移性肝がんと原発性肝がんの症例に分けることができます。転移性肝がんの生物学的特徴や進行パターンは、原発性肝悪性腫瘍とは異なる治療上の配慮を必要とすることが多いため、この区分は極めて重要です。その結果、このセグメンテーションは治療プロトコールに反映されるだけでなく、特殊な標的療法に向けた研究開発努力の方向付けにもなります。

適用手技に基づくセグメンテーションは、肝腫瘍、葉面療法、分節療法を区別することによって、われわれの理解をさらに深めるものです。それぞれの手技は、腫瘍の形態や患者の解剖学的構造の微妙な違いに対処する独自のアプローチを提供し、それによって個々の臨床ニーズに応えます。最後に、エンドユーザー別のセグメンテーションは、様々なヘルスケア提供環境における展望を描くのに役立ちます。外来手術センターやがん研究機関から総合病院まで、エンドユーザーの多様性は、放射性塞栓療法技術の広範な採用を示しており、市場の広範な範囲と適応性を際立たせています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で肝臓がんと肝硬変の罹患率が増加
    • 世界中のヘルスケアインフラの拡大
    • 世界中のがん治療への政府の支援と資金提供
  • 抑制要因
    • 放射線塞栓術に伴う高額な費用
  • 機会
    • 病院とバイオテクノロジー企業との戦略的提携による新しい治療法の革新
    • 生産コストを下げ、アクセス性を高めるための代替放射性同位元素の開発
  • 課題
    • 放射性塞栓療法の複雑な規制承認と償還問題
• 市場セグメンテーション分析
  • 治療カテゴリー：放射性塞栓療法における治療的治療への嗜好の高まり
  • 応募手順：放射性塞栓療法肝腫瘍治療の適用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 放射性塞栓療法市場：コンポーネント別

• カテーテル
• 核医学機器
• 放射性ミクロスフェア
• X線装置

第7章 放射性塞栓療法市場治療カテゴリー別

• 治癒的
• 緩和

第8章 放射性塞栓療法市場腫瘍の種類別

• 転移性肝がん
• 原発性肝がん

第9章 放射性塞栓療法市場申請手続き

• 肝臓腫瘍
• 葉状療法
• セグメント療法

第10章 放射性塞栓療法市場：エンドユーザー別

• 外来手術センター
• がん調査機関
• 病院

第11章 南北アメリカの放射性塞栓療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の放射性塞栓療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの放射性塞栓療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Bayer AG
• Becton Dickinson & Company
• Boston Scientific Corporation
• Cook Medical
• Elekta AB
• Fortis Healthcare Limited
• Hamilton Health Sciences
• Mayo Clinic Health System
• Merit Medical Systems, Inc.
• Nordion Inc.
• Northwestern Memorial HealthCare.
• Radiological Society of North America, Inc.
• Siemens AG
• Sirtex Medical Pty Ltd
• Stryker Corporation
• Terumo Corporation
• United HealthCare Services, Inc

LIST OF FIGURES

• FIGURE 1. RADIOEMBOLIZATION THERAPY MARKET MULTI-CURRENCY
• FIGURE 2. RADIOEMBOLIZATION THERAPY MARKET MULTI-LANGUAGE
• FIGURE 3. RADIOEMBOLIZATION THERAPY MARKET RESEARCH PROCESS
• FIGURE 4. RADIOEMBOLIZATION THERAPY MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. RADIOEMBOLIZATION THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RADIOEMBOLIZATION THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 43. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 44. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 70. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 71. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 75. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 76. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 161. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 162. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 181. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 182. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 186. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 187. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 236. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

The Radioembolization Therapy Market was valued at USD 1.09 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 5.90%, reaching USD 1.54 billion by 2030.

Radioembolization therapy has emerged as a groundbreaking solution in the treatment landscape for liver cancers, offering hope where conventional treatments have often fallen short. This executive summary explores the intricate details of a market that stands at the convergence of advanced medical technology and critical patient care. In an era of rapidly evolving innovations and intensified focus on targeted oncological therapies, our analysis encapsulates current trends, emerging challenges, and opportunities in this transformative field.

In recent years, medical professionals and researchers have increasingly turned to radioembolization as a minimally invasive procedure that targets liver tumors with high precision, thereby reducing collateral damage to healthy tissues. This controlled form of internal radiation not only underscores the significance of personalization in cancer treatment but also redefines standards of care in the fight against both primary and metastatic liver cancers. The strategic insights provided here are designed to offer decision-makers, healthcare innovators, and industry leaders a comprehensive overview of the current market dynamics, key growth drivers, and areas ripe for further innovation.

Through an in-depth exploration of clinical applications, technological advancements, and the influence of pivotal industry players, we aim to present a roadmap that supports both immediate tactical shifts and long-term strategic planning. With a balanced perspective that merges clinical evidence with market data analysis, this report serves as an essential guide for stakeholders seeking to navigate the complexities of the radioembolization therapy space.

Transformative Shifts Driving the Modern Radioembolization Therapy Landscape

The landscape of radioembolization therapy has undergone significant transformations in recent years. Technological innovations, coupled with an increased understanding of tumor biology and radiation physics, have catalyzed a paradigm shift in treatment strategies. This evolution is underscored by the integration of advanced imaging technologies, precision-engineered delivery systems, and novel radioactive microspheres designed to deliver targeted doses more effectively than ever before.

Advancements in catheter design have improved the precision and safety of the infusion process, further boosting the therapeutic index of radioembolization treatments. Complementary to these technical improvements is the adoption of imaging modalities that enhance treatment planning and real-time monitoring, thereby driving greater clinical confidence. Additionally, the evolving regulatory frameworks and reimbursement policies across various regions have paved the way for increased accessibility and acceptance of these innovative treatment procedures.

Increasing collaborations among physicians, engineers, and medical device manufacturers have also accelerated the pace of innovation. Stakeholders are now able to harness the synergy between clinical expertise and technological prowess, thereby enhancing the overall effectiveness of radioembolization procedures. With a focus on personalized treatment regimens, the market is shifting from a one-size-fits-all approach to a more customized, precision-based methodology, further solidifying its role in modern oncological care.

This transformative journey is not without challenges. The integration of new technologies into traditional healthcare frameworks requires extensive training and a recalibration of practitioner protocols. Nonetheless, the potential benefits in terms of improved patient outcomes and reduced systemic toxicities are driving the continuous evolution of therapeutic strategies in this space.

Segmentation Insights Illuminating Market Dynamics

A deeper understanding of the radioembolization therapy market emerges from a precise analysis of several key segmentation dimensions. The market is dissected based on component analysis, which includes sophisticated devices such as catheters, nuclear medicine equipment, radioactive microspheres, and x-ray equipment. This segmentation allows us to appreciate how each component plays a pivotal role in facilitating a seamless treatment process, where technology meets safety standards and operational efficiency.

Furthermore, the market is analyzed through the lens of treatment categories, distinguishing between curative and palliative approaches. Such differentiation underscores the dual nature of radioembolization therapy, where some patients seek radical treatment with the intent to eradicate the disease, while others opt for palliative care aimed at improving quality of life in the face of intractable conditions. This duality has spurred innovation as manufacturers strive to balance clinical efficacy with patient-centric outcomes.

In addition, tumor type segmentation provides an insightful breakdown into cases of metastatic liver cancer versus primary liver cancer. This distinction is crucial, as the biological characteristics and progression patterns of metastatic liver cancer often require different therapeutic considerations compared to primary liver malignancies. As a result, this segmentation not only informs treatment protocols but also directs research and development efforts toward specialized, targeted therapies.

The segmentation based on application procedure further refines our understanding by differentiating between liver tumor, lobar therapy, and segmental therapy. Each procedure offers a unique approach to addressing the nuances of tumor morphology and patient anatomy, thereby catering to individualized clinical needs. Finally, segmentation by end-user helps chart the landscape across various healthcare delivery settings. From ambulatory surgical centers and cancer research institutes to comprehensive hospitals, the diversity in end-users points to a broad-based adoption of radioembolization therapy techniques, accentuating the market's expansive reach and adaptability.

Based on Component, market is studied across Catheters, Nuclear Medicine Equipment, Radioactive Microspheres, and X-Ray Equipment.

Based on Treatment Category, market is studied across Curative and Palliative.

Based on Tumor Type, market is studied across Metastatic Liver Cancer and Primary Liver Cancer.

Based on Application Procedure, market is studied across Liver Tumour, Lobar Therapy, and Segmental Therapy.

Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Research Institutes, and Hospitals.

Regional Insights Highlighting Global Trends

The global footprint of radioembolization therapy is marked by distinct regional trends that reflect varying degrees of market maturity and healthcare infrastructure readiness. In the Americas, robust healthcare systems and substantial investments in oncological research have supported the early adoption and integration of radioembolization therapy. Clinicians and healthcare providers in this region are leveraging advanced technologies to push the boundaries of personalized medicine.

Across Europe, the Middle East, and Africa, regulatory dynamics, coupled with a balanced emphasis on both innovative research and cost-effective care solutions, are shaping the market landscape. European nations, in particular, have seen a rapid acceleration in clinical research alongside an emphasis on safety protocols and treatment efficacy. Meanwhile, emerging markets within the Middle East and Africa are gradually building capacity, laying the groundwork for a more extensive uptake of these advanced therapeutic solutions.

In the Asia-Pacific region, rapid economic growth, government initiatives, and strategic partnerships are driving significant investments in healthcare innovation. The region is witnessing a swift expansion in infrastructural capabilities and a surge in clinical trials, underpinning a growing interest in adopting radioembolization therapy at scale. The confluence of progressive health policies and increased public awareness ensures that radioembolization therapy will continue to play a central role in addressing the rising cancer burden in these territories.

These regional insights not only highlight the market's diversity but also serve as a catalyst for cross-regional knowledge sharing and strategic collaborations. The global nature of the market is driving a convergence of best practices that benefit all stakeholders and ultimately lead to enhanced patient care worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-Depth Company Insights Shaping the Market Evolution

At the core of radioembolization therapy's innovation and growth are the key companies that continuously push the envelope of medical technology. Industry leaders such as Bayer AG, Becton Dickinson & Company, Boston Scientific Corporation, and Cook Medical are at the forefront of research and development, leveraging vast resources to innovate new solutions for precise treatment delivery. This competitive landscape is further enriched by players like Elekta AB, Fortis Healthcare Limited, and Hamilton Health Sciences, whose contributions highlight the integration of clinical expertise with innovative technological advancements.

Innovative healthcare institutions including the Mayo Clinic Health System, Merit Medical Systems, Inc., Nordion Inc., and Northwestern Memorial HealthCare are driving clinical excellence and setting high benchmarks in therapeutic efficacy. Furthermore, the Radiological Society of North America, Inc. plays a crucial role in fostering educational initiatives and promoting research collaborations, while global giants such as Siemens AG and Sirtex Medical Pty Ltd are pivotal in optimizing treatment dosimetry and procedural accuracy.

Other influential entities such as Stryker Corporation, Terumo Corporation, and United HealthCare Services, Inc. enrich the competitive environment by focusing on process innovation, patient safety measures, and cost containment strategies. The collaboration and competition among these companies not only drive technological progress but also enhance the overall standards of care, ensuring that patients receive the most advanced and effective treatments available.

Each of these industry leaders contributes unique insights based on their regional dominance, product portfolios, and research trajectories. Their continued innovation is instrumental in addressing the evolving needs of the radioembolization therapy market, ensuring a trajectory of sustained growth and improved patient outcomes.

The report delves into recent significant developments in the Radioembolization Therapy Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Becton Dickinson & Company, Boston Scientific Corporation, Cook Medical, Elekta AB, Fortis Healthcare Limited, Hamilton Health Sciences, Mayo Clinic Health System, Merit Medical Systems, Inc., Nordion Inc., Northwestern Memorial HealthCare., Radiological Society of North America, Inc., Siemens AG, Sirtex Medical Pty Ltd, Stryker Corporation, Terumo Corporation, and United HealthCare Services, Inc. Actionable Strategic Recommendations for Industry Leaders

Industry leaders can capitalize on emerging opportunities in the radioembolization therapy market by embracing a multi-faceted approach that aligns with both current trends and future advancements. First, investing in research and innovation remains paramount. As technology continues to evolve, allocating resources towards the development of next-generation delivery systems and enhanced imaging modalities will be critical. Leaders should focus on partnerships with research institutions and clinical experts to foster an environment of collaborative innovation that accelerates the translation of laboratory breakthroughs to clinical application.

Second, market penetration and global outreach should be driven by a deep understanding of regional dynamics. Customizing product offerings to meet the specific clinical and regulatory requirements of diverse markets will improve adoption rates. This involves tailoring devices and protocols for varied healthcare settings, which range from advanced hospitals to emerging cancer research centers. A data-driven approach to regional market analysis can guide strategic investment and inform the development of localized training programs, ensuring that new technologies are efficiently integrated into current clinical practices.

Third, enhancing patient-centric strategies through personalized therapy protocols can provide a competitive edge. By leveraging segmentation insights based on treatment category, tumor type, and application procedures, companies can align their product development efforts with real-world patient needs. This strategy not only improves treatment outcomes but also builds greater trust and recognition among both clinicians and patients.

Moreover, forging strategic alliances across the value chain-including partnerships with technology providers, regulatory advisors, and healthcare institutions-can drive synergies that accelerate market growth. Through collaborative ventures, companies can share best practices, streamline manufacturing processes, and overcome common regulatory hurdles.

Lastly, adopting proactive communication strategies to educate clinicians, patients, and regulatory bodies will be crucial for market expansion. An informed market is more likely to embrace innovative therapeutic solutions, thereby creating a favorable ecosystem for sustained growth. Effective educational campaigns and stakeholder engagement initiatives should form an integral part of any company's strategy moving forward.

By implementing these actionable recommendations, industry leaders can not only enhance their competitive positioning but also drive meaningful advancements in clinical practice, ultimately improving the standard of care for patients worldwide.

Conclusion: Summarizing the Key Insights

In summary, the evolving landscape of radioembolization therapy is marked by significant technological advances, regional diversification, and complex market dynamics that necessitate adaptive strategies by industry stakeholders. Our analysis underscores the importance of an integrated approach that leverages both technological innovation and strategic collaborations to meet the rising demand for personalized cancer treatments.

From understanding the nuances of market segmentation based on component, treatment category, tumor type, application procedure, and end-users to appreciating the subtle regional influences across the Americas, Europe, Middle East & Africa, and Asia-Pacific, it is evident that a one-size-fits-all strategy is ineffective in this complex domain. The diverse contributions of key companies reaffirm the need for continuous innovation and strategic investments that align product offerings with clinical requirements. These insights serve as a roadmap for how to navigate the challenges and opportunities in a market that is not only competitive but is also rapidly evolving.

As the radioembolization therapy landscape continues to mature, ensuring that research, innovation, and regional insights are adequately integrated into strategic planning will be essential. This integrated approach will support better clinical outcomes and drive sustained market growth, ensuring that cutting-edge treatments are accessible to patients globally.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of liver cancer and cirrhosis among patients globally
    • 5.1.1.2. Expansion in healthcare infrastructure worldwide
    • 5.1.1.3. Government support and funding for cancer treatment initiatives worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with radioembolization procedures
  • 5.1.3. Opportunities
    • 5.1.3.1. Strategic partnerships between hospitals and biotechnology firms for innovating novel therapies
    • 5.1.3.2. Development of alternative radioisotopes for lowering production costs and increasing accessibility
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory approvals and reimbursement issues for radioembolization therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Category: Increasing preference for curative treatments in radioembolization therapy
  • 5.2.2. Application Procedure: Expanding application of radioembolization therapy liver tumor treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Radioembolization Therapy Market, by Component

• 6.1. Introduction
• 6.2. Catheters
• 6.3. Nuclear Medicine Equipment
• 6.4. Radioactive Microspheres
• 6.5. X-Ray Equipment

7. Radioembolization Therapy Market, by Treatment Category

• 7.1. Introduction
• 7.2. Curative
• 7.3. Palliative

8. Radioembolization Therapy Market, by Tumor Type

• 8.1. Introduction
• 8.2. Metastatic Liver Cancer
• 8.3. Primary Liver Cancer

9. Radioembolization Therapy Market, by Application Procedure

• 9.1. Introduction
• 9.2. Liver Tumour
• 9.3. Lobar Therapy
• 9.4. Segmental Therapy

10. Radioembolization Therapy Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Cancer Research Institutes
• 10.4. Hospitals

11. Americas Radioembolization Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Radioembolization Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Radioembolization Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. SINTX Technologies partners with NED Medical under a joint development agreement
  • 14.3.2. ABK Biomedical received FDA approval to proceed to Stage 2 of their Route90 pivotal study,
  • 14.3.3. Juravinski Hospital and Cancer Centre introduced radioembolization to treat liver cancer
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Becton Dickinson & Company
• 3. Boston Scientific Corporation
• 4. Cook Medical
• 5. Elekta AB
• 6. Fortis Healthcare Limited
• 7. Hamilton Health Sciences
• 8. Mayo Clinic Health System
• 9. Merit Medical Systems, Inc.
• 10. Nordion Inc.
• 11. Northwestern Memorial HealthCare.
• 12. Radiological Society of North America, Inc.
• 13. Siemens AG
• 14. Sirtex Medical Pty Ltd
• 15. Stryker Corporation
• 16. Terumo Corporation
• 17. United HealthCare Services, Inc